The Role of ATP in Primary Prevention Patients

Multiple clinical studies demonstrate that ATP plays a valuable role in treating primary prevention ICD patients.2,3,4,6 This page reviews the clinical evidence behind the use of ATP in treating primary prevention patients. It discusses the efficacy, safety, utility, and impact on quality of life ATP can provide.


1 Arenal A, Proclemer A, Kloppe A, et al. Different impact of long-detection interval and anti-tachycardia pacing in reducing unnecessary shocks: data from the ADVANCE III trial. Europace. 2016; 18(11): 1719-1725. doi:10.1093/europace/euw032
2 Sweeney, MO, Ellenbogen KA, Tang ASL, et al. Differences in Effects of Electrical Therapy Type on Health Care Utilization in the MVP ICD Trial. HRS Conference. Denver, USA; 2010.
3 Wathen M, DeGroot PJ, Sweeney MO, et al. Prospective randomized multicenter trial of empirical antitachycardia pacing versus shocks for spontaneous rapid ventricular tachycardia in patients with implantable cardioverter-defibrillators: Pacing Fast Ventricular Tachycardia Reduces Shock Therapies (PainFREE Rx II) trial results Circulation. 2004; 110(17): 2591-2596. doi: 10.1161/01.CIR.0000145610.64014.E4
4 Sweeney MO, Sherfesee L, DeGroot PJ, Wathen MS, Wilkoff BL. Differences in effects of electrical therapy type for ventricular arrhythmias on mortality in implantable cardioverter-defibrillator patients. Heart Rhythm. 2010; 7(3): 353-60. doi: 10.1016/j.hrthm.2009.11.027. 
5 Mastenbroek MH, Pedersen SS, van der Tweel I, Doevendans PA, Meine M. Results of ENHANCED Implantable Cardioverter Defibrillator Programming to Reduce Therapies and Improve Quality of Life (from the ENHANCED-ICD Study). Am J Cardiol. 2016; 117(4): 596-604. doi: 10.1016/j.amjcard.2015.11.052
6 Fischer Al, Ousdigian KT, Johnson JW, Gillbert JM, Wilkoff BL. The impact of atrial fibrillation with rapid ventricular rates and device programming on shocks in 106,513 ICD and CRT-D patients. Heart Rhythm. 2012; 9(1): 24-31. doi: 10.1016/j.hrthm.2011.08.005. 
7 Landolina M, Lunati M, Boriani G, et al. Ventricular antitachycardia pacing therapy in patients with heart failure implanted with a cardiac resynchronization therapy defibrillator device: Efficacy, safety, and impact on mortality. Heart Rhythm. 2016; 13(2): 472-480. doi: 10.1016/j.hrthm.2015.10.022.
8 Sun S, Johnson J, DeGroot P, Brown ML, Obel O. Effect of ICD Therapies on Mortality in the OMNI Trial. J Cardiovasc Electrophysiol. 2016; 27(2): 192-199. doi: 10.1111/jce.12860.
9 Wathen MS, Volosin KJ, Sweeney MO, et al. Ventricular anti-tachycardia pacing by implantable cardioverter defibrillators reduces shocks for inappropriately detected supraventricular tachycardia [abstract]. Heart Rhythm. 2004; 1: S148. 
10 Sears S, Whited A, Koehler J, Gunderson B. Examination of the differential impacts of antitachycardia pacing vs. shock on patient activity in the EMPIRIC study. Europace. 2015; 17(3): 417-423. doi: 10.1093/europace/euu305 
11 Aurrichio Al, Schloss EJ, Kurita T, et al. Low inappropriate shock rates in patients with single- and dual/triple-chamber implantable cardioverter-defibrillators using a novel suite of detection algorithms: PainFree SST trial primary results. Heart Rhythm. 2015; 12(5): 926–936 doi: 10.1016/j.hrthm.2015.01.017
12 Strickberger SA, Canby R, Cooper J, et al. Association of Antitachycardia Pacing or Shocks With Survival in 69,000 Patients With an Implantable Defibrillator. J Cardiovasc Electrophysiol. 2017; 28(4): 416-422. doi: 10.1111/jce.13170 
13  Moss AJ, Schuger C, Beck CA, et al. Reduction in inappropriate therapy and mortality through ICD programming. N Engl J Med. December 13, 2012;367(24):2275-2283.
14 Wilkoff BL, Williamson BD, Stern RS, et al. Strategic programming of detection and therapy parameters in implantable cardioverter-defibrillators reduces shocks in primary prevention patients: results from the PREPARE (Primary Prevention Parameters Evaluation) study. J Am Coll Cardiol. August 12, 2008;52(7):541-550.

Last updated: 
17 May 2017